Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 178

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 5
Chunk 178
---
4, €0.5 million in 2023 and €1.4 million in 2022;
------------------------------------------------------------------------------------------------------------------------------------------------

●   investments of €0.5 million in 2022, to build the extension of the existing Grifols International building and 2-8ºC chamber for 2,000 pallets; and
-------------------------------------------------------------------------------------------------------------------------------------------------------

●   Investments of €2.7 million in 2023 to build a new manufacturing line for a contract manufacturing product.
---------------------------------------------------------------------------------------------------------------
Clayton site (North Carolina, United States):

●   investments for the construction of a new immunoglobulins’ purification and filling plant of €0.7 million in 2024, €11.4 million in 2023 and €20.7 million in 2022;
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments for the construction of a new fractionation plant of €1.0 million in 2023 and €32,176 in 2022 (no investments were made in 2024);
-------------------------------------------------------------------------------------------------------------------------------------------------

●   expansion of Grifols’ current waste water pretreatment plant in Clayton to meet Town of Clayton permit limits, with investments of €4.3 million in 2023 and €12.4 million in 2022;
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments to enhance cooling capacity buildings of €0.5 million in 2023 and €6.8 million in 2022; and
-----------------------------------------------------------------------------------------------------------

●   Investments of €5.5 million in 2024 to expand the fibrinogen production capacity.
-------------------------------------------------------------------------------------
114

Los Angeles (California, United States):

●   investments in new quality and risk management systems of €0.8 million in 2023 and €3.0 million in 2022;
------------------------------------------------------------------------------------------------------------

●   investments to build a new warehouse for Gamunex incubators of €0.1 million in 2024, €2.9 million in 2023 and €0.8 million in 2022,
---------------------------------------------------------------------------------------------------------------------------------------

●   Investment of €0.7 million in 2023 and €2 million in 2024 to increase Gamunex, Purified and WFI production; and
-------------------------------------------------------------------------------------------------------------------

●   investments to increase our albumin purification capacity and including a new presentation in ready-to-use flexible bags of €0.5 million in 2022.
-----------------------------------------------------------------------------------------------------------------------------------------------------
Dublin (Ireland):

●   investments to build a new headquarters, global operations and logistics center to serve as part of the new global operations center of the